People
Milestone Pharmaceuticals names new director
5 April 2019 -

Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, announced yesterday that it has named Michael Tomsicek as its director.

Presently, Tomsicek is the chief financial officer of biopharmaceutical company, CRISPR Therapeutics. At Milestone he will also serve as chairman of the board's Audit Committee.

Tomsicek has more than 20 years of corporate and financial leadership experience to Milestone. Prior to joining CRISPR, he served as the chief financial officer of Abiomed. He has also served as chief financial officer at Cubist Pharmaceuticals, where he held various roles in financial operations, investor relations, and corporate strategy. During his tenure at Cubist, he participated in the transition of the company following its acquisition by Merck. He also served in a series of financial leadership positions at General Electric Healthcare, where he oversaw the global ultrasound business.

Login
Username:

Password: